Emerging drugs for the treatment of acromegaly

Claudia Campana, Giuliana Corica, Federica Nista, Francesco Cocchiara, Giulia Graziani, Keyvan Khorrami, Marta Franco, Mara Boschetti, Diego Ferone, Federico Gatto

Research output: Contribution to journalReview articlepeer-review


Introduction: Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered life-long. To date, almost 30% of patients treated with the currently available medical therapies do not achieve biochemical control. Areas covered: This review focuses on new drugs in development for acromegaly. In detail, we provide an overview of the new molecules designed to improve disease control rate (such as novel somotostatin receptor ligands and antisense oligonucleotides), as well as the new formulations of existing medications aiming to improve patients’ compliance (e.g. oral or long-acting subcutaneous octreotide). Expert opinion: The constant progresses in the medical treatment of acromegaly could lead to an individualized therapy based on tumor, as well as patient’s characteristics. Besides disease control, patient’s need represents a major target of medical treatment in chronic diseases such as acromegaly, in order to improve compliance to therapy and patients’ quality of life.

Original languageEnglish
JournalExpert Opinion on Emerging Drugs
Publication statusAccepted/In press - 2020


  • Acromegaly
  • GH
  • IGF-1
  • innovative treatments
  • medical treatment
  • somatostatin receptor ligands

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Emerging drugs for the treatment of acromegaly'. Together they form a unique fingerprint.

Cite this